Technology area: Biotechnology & Pharmaceuticals
22 pending office actions • 15 art units • 22 examiners • 0 of 22 (0%) have an AI response strategy ready • 16 patents granted in the last 365 days
The Wistar Institute has 21 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 21 distinct examiners across 15 distinct art units, showing a large and widely distributed prosecution portfolio. This scale requires systematic docket controls, consistent recordkeeping, and an approach that separates portfolio-wide policy from application-specific decisions.
SHIAO, REI TSANG is the busiest examiner, with 1 pending matter. The data therefore shows no concentration of the pending matters in a single examiner, even though the portfolio has substantial overall activity.
Counsel should use centralized review to identify recurring claim, written-description, and prior-art themes across the 15 art units. Responses, interviews, and amendment decisions should then be tailored to each examiner, because the 21 matters are distributed across 21 examiner assignments.
Based on the USPTO statutory response window for each pending office action. 10 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 10 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 4 (18%) |
| §102 only | 2 (9%) |
| §112 only | 5 (23%) |
| Double-patenting + other | 2 (9%) |
| Multi-statute (no §101) | 9 (41%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SHIAO, REI TSANG | 1 | 79.9% | -33.5% |
| GURLEY, JAMI MICHELLE | 1 | 54.8% | +14.3% |
| EDGINGTONGIORDANO, FRANCESCA | 1 | 71.8% | +29.4% |
| SZNAIDMAN, MARCOS L | 1 | 37.4% | +16.1% |
| BOESEN, AGNIESZKA | 1 | 68.6% | +21.8% |
| STUBBS, JOHN THOMAS | 1 | — | — |
| GODDARD, LAURA B | 1 | 50.8% | +13.6% |
| ALAM, DANYAL HASSAN | 1 | 66.7% | +0.0% |
| FOLEY, SHANON A | 1 | 73.3% | +18.2% |
| ALLEN, MICHAEL D | 1 | 31.9% | +48.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17995539 | REAWAKENING OF DORMANT TUMOR CELLS BY MODIFIED LIPIDS DERIVED FROM STRESS ACTIVATED NEUTROPHILS | KONOPKA, CATHERINE ANNE | 182d overdue |
| 17907697 | Synthetic Soluble Receptor Mimics and Methods of Use for Treatment of COVID-19 | ROSSI, JULIA ANNE LORRAIN | 167d overdue |
| 18064482 | LARGE AND SMALL T ANTIGENS OF MERKEL CELL POLYOMAVIRUS, NUCLEIC ACID CONSTRUCTS AND VACCINES MADE THEREFROM, AND METHODS OF USING SAME | FOLEY, SHANON A | 138d overdue |
| 18001116 | CORONAVIRUS DISEASE 2019 (COVID-19) COMBINATION VACCINE | ALLEN, MICHAEL D | 79d overdue |
| 18588643 | MAGE-A VACCINES AND METHODS OF TREATMENT USING THE SAME | EDGINGTONGIORDANO, FRANCESCA | 37d overdue |
| 18699081 | Novel Immune Cell Engagers For Immunotherapy | GURLEY, JAMI MICHELLE | — |
| 18534114 | COMBINATION THERAPIES TARGETING MITOCHONDRIAL BIOGENESIS FOR CANCER THERAPY | SZNAIDMAN, MARCOS L | — |
| 18469813 | PROCESSES FOR PREDICTING THERAPY BENEFITS | STUBBS, JOHN THOMAS | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18064482 | LARGE AND SMALL T ANTIGENS OF MERKEL CELL POLYOMAVIRUS, NUCLEIC ACID CONSTRUCTS AND VACCINES MADE THEREFROM, AND METHODS OF USING SAME | FOLEY, SHANON A | 138d overdue |
| 18001116 | CORONAVIRUS DISEASE 2019 (COVID-19) COMBINATION VACCINE | ALLEN, MICHAEL D | 79d overdue |
| 18588643 | MAGE-A VACCINES AND METHODS OF TREATMENT USING THE SAME | EDGINGTONGIORDANO, FRANCESCA | 37d overdue |
| 18556414 | GLYCAN MODIFIED SPIKE RECEPTOR BINDING DOMAIN NANOPARTICLES AND METHOD OF USE THEREOF AS A CORONAVIRUS DISEASE 2019 (COVID-19) VACCINE | BOESEN, AGNIESZKA | 84d |
| 18699081 | Novel Immune Cell Engagers For Immunotherapy | GURLEY, JAMI MICHELLE | — |
| 18534114 | COMBINATION THERAPIES TARGETING MITOCHONDRIAL BIOGENESIS FOR CANCER THERAPY | SZNAIDMAN, MARCOS L | — |
| 18551078 | DNA-ENCODED BISPECIFIC ANTIBODIES TARGETING IL13Ra2 AND METHODS OF USE IN CANCER THERAPEUTICS | GODDARD, LAURA B | — |
| Art Unit | Apps |
|---|---|
| 1671 | 3 |
| 1647 | 2 |
| 1643 | 2 |
| 1672 | 2 |
| 1642 | 2 |
| 1615 | 2 |
| 1691 | 1 |
| 1628 | 1 |
| 1686 | 1 |
| 1635 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18856686 | DELIVERY SYSTEM TO TARGET GRAM-NEGATIVE BACTERIA | SHIAO, REI TSANG | 1691 | §112 | Non-Final OA | — | Pending | Oct 14, 2024 |
| 18699081 | Novel Immune Cell Engagers For Immunotherapy | GURLEY, JAMI MICHELLE | 1647 | §102§103§112 | Non-Final OA | — | Pending | Apr 05, 2024 |
| 18588643 | MAGE-A VACCINES AND METHODS OF TREATMENT USING THE SAME | EDGINGTONGIORDANO, FRANCESCA | 1643 | §101§102§112Other | Non-Final OA | 37d overdue | Pending | Feb 27, 2024 |
| 18534114 | COMBINATION THERAPIES TARGETING MITOCHONDRIAL BIOGENESIS FOR CANCER THERAPY | SZNAIDMAN, MARCOS L | 1628 | §102§112 | Non-Final OA | — | Pending | Dec 08, 2023 |
| 18556414 | GLYCAN MODIFIED SPIKE RECEPTOR BINDING DOMAIN NANOPARTICLES AND METHOD OF USE THEREOF AS A CORONAVIRUS DISEASE 2019 (COVID-19) VACCINE | BOESEN, AGNIESZKA | 1672 | §102§112DP | Non-Final OA | 84d | Pending | Oct 20, 2023 |
| 18469813 | PROCESSES FOR PREDICTING THERAPY BENEFITS | STUBBS, JOHN THOMAS | 1686 | §101§103§112 | Non-Final OA | — | Pending | Sep 19, 2023 |
| 18551078 | DNA-ENCODED BISPECIFIC ANTIBODIES TARGETING IL13Ra2 AND METHODS OF USE IN CANCER THERAPEUTICS | GODDARD, LAURA B | 1642 | §102§103§112Other | Final Rejection | — | Pending | Sep 18, 2023 |
| 18252115 | COMPOSITIONS AND METHODS FOR PREDICTING RISK OF MODERATE TO SEVERE COVID-19 DISEASE | ALAM, DANYAL HASSAN | 1672 | §101§102§103§112 | Final Rejection | — | Pending | May 08, 2023 |
| 18064482 | LARGE AND SMALL T ANTIGENS OF MERKEL CELL POLYOMAVIRUS, NUCLEIC ACID CONSTRUCTS AND VACCINES MADE THEREFROM, AND METHODS OF USING SAME | FOLEY, SHANON A | 1671 | §102§112Other | Non-Final OA | 138d overdue | Pending | Dec 12, 2022 |
| 18001116 | CORONAVIRUS DISEASE 2019 (COVID-19) COMBINATION VACCINE | ALLEN, MICHAEL D | 1671 | §103§112Other | Final Rejection | 79d overdue | Pending | Dec 08, 2022 |
| 17997963 | DNA ANTIBODY CONSTRUCTS FOR USE AGAINST HEPATITIS B VIRUS | XIAO, YAN | 1642 | §112 | Final Rejection | 28d | Pending | Nov 04, 2022 |
| 17995539 | REAWAKENING OF DORMANT TUMOR CELLS BY MODIFIED LIPIDS DERIVED FROM STRESS ACTIVATED NEUTROPHILS | KONOPKA, CATHERINE ANNE | 1635 | §102§103§112 | Non-Final OA | 182d overdue | Pending | Oct 05, 2022 |
| 17907697 | Synthetic Soluble Receptor Mimics and Methods of Use for Treatment of COVID-19 | ROSSI, JULIA ANNE LORRAIN | 1615 | §102§103§112 | Non-Final OA | 167d overdue | Pending | Sep 29, 2022 |
| 17905143 | TREATMENT OF CARM1-OVEREXPRESSING AND/OR ARID1A MUTANT CANCERS WITH IRE-1/XBP-1 INHIBITORS | SIMMONS, CHRIS E | 1622 | §103§112 | Non-Final OA | — | Pending | Aug 26, 2022 |
| 17759649 | CD40-L BLOCKADE TO ENHANCE SYNTHETIC ANTIBODY THERAPY | BUNNER, BRIDGET E | 1647 | §102 | Non-Final OA | — | Pending | Jul 28, 2022 |
| 17812060 | Methods and Compositions for the Diagnosis of Ovarian Cancer | ZHANG, KAIJIANG | 1684 | §102 | Final Rejection | — | Pending | Jul 12, 2022 |
| 17787729 | VACCINES AGAINST AFRICAN SWINE FEVER VIRUS, AND METHODS OF USING SAME | SIFFORD, JEFFREY MARK | 1671 | §101§102§103§112DP | Non-Final OA | — | Pending | Jun 21, 2022 |
| 17634968 | NOVEL LOX-1 ANTIBODY COMPOSITIONS, LOX1 NEUTRALIZATION ASSAY AND METHODS OF TREATMENT USING SAME | SHUPE, ELIZABETH A | 1643 | §112 | Non-Final OA | 162d overdue | Pending | Feb 12, 2022 |
| 17427434 | DNA-ENCODED BISPECIFIC T-CELL ENGAGERS TARGETING CANCER ANTIGENS AND METHODS OF USE IN CANCER THERAPUTICS | CUNNINGCHEN, KATHLEEN MARY | 1646 | §102§103§112DP | Final Rejection | — | Pending | Jul 30, 2021 |
| 16943947 | Methods for Monitoring Polymorphonuclear Myeloid Derived Suppressor Cells and Compositions and Methods of Treatment of Cancer | FORD, VANESSA L | 1674 | §112 | Final Rejection | 6d | Pending | Jul 30, 2020 |
| 16347861 | DNA ANTIBODY CONSTRUCTS FOR USE AGAINST LYME DISEASE | ZEMAN, ROBERT A | 1645 | §112 | Non-Final OA | 10d overdue | Pending | May 07, 2019 |
| 18115945 | Compositions and Methods for Treating, Ameliorating and/or Preventing Cancer and Kits for the Same | SCOTLAND, REBECCA LYNN | 1615 | §102§103§112 | Final Rejection | — | Pending | Mar 01, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialThe Wistar Institute has 22 pending office actions as of October 2026, spread across 15 art units and 22 examiners.
Rei Tsang Shiao has the most, with 1 of The Wistar Institute's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
